Profit before tax jumped 64% to Rs. 226 crore, while the company maintained robust investment in innovation with net R&D spend of Rs. 249 crore
The Profit After Tax (PAT) for Q3 FY26 was Rs 49.68 crore, compared to Rs 46.78 crore in Q3 FY25
Occlutech develops, manufactures, and commercialises medical devices for congenital heart disease, stroke prevention, and heart failure
Motorica India conducted a specialised masterclass led by Shumaev, centred on real-life rehabilitation scenarios and personalised therapy programs before and after prosthetic fitting
The company has commissioned a new plant at Khanna (Punjab), which has begun commercial production
The unveiling marks Time Medical India’s entry into next-generation helium-free MRI technology
Capital expenditure stood at Rs. 405 crore to date against a planned Rs. 700 crore for FY26
These results were consistent across all clinically relevant patient subgroups regardless of key patient characteristics like age or sex, the cause of stroke or the severity of the stroke
Subscribe To Our Newsletter & Stay Updated